Faith Davies, MD, shares insights from the IMS 2024 session on high-risk disease, highlighting the debut of a unified high-risk definition. This new framework incorporates 17p deletions, mutations,…
Multiple myeloma is a significant yet lesser-known type of blood cancer. In this Mayo Clinic Health System video, discover key insights about multiple myeloma, including its symptoms, prevalence,…
Recent Videos in Multiple Myeloma Content Hub Page 3
Niels van de Donk, MD, PhD, Professor of Cancer Immunology, VU University Medical Center, Amsterdam, Netherlands, discusses #BCMA #CART therapy in #multiplemyeloma.
Michael Banks, MD, announces the launch of the Multiple Myeloma Content Hub on The Doctor’s Channel. Check back soon for interviews with thought leaders in the space, case…
Raj Chakraborty, MD, assistant professor of medicine at Columbia University Irving Medical Center, discusses promising results from current clinical trials for newly diagnosed multiple myeloma. The GRIFFIN trial…
In an interview conducted during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Saad Usmani, MD, MBBS, MBA, of the Levine Cancer Institute in…
In an interview recorded during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020, Luciano Costa, MD, PhD, of UAB School of Medicine, Birmingham, AL,…
Brian G. M. Durie, MD, chairman of the board of the International Myeloma Foundation, discusses whether patients with borderline high-risk smoldering myeloma should begin treatment early. Some treatments…
In a sequencing study of 82 patients with smoldering multiple myeloma, there were fewer NRAS and FAM46C mutations and with fewer adverse translocations – del(1p), del(14q), del(16q), and…
